SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended ...
Vir has a promising pipeline, and expects to report data this year on several phase 2 clinical trials. Vir's revenue rose by 133.4% last year. The Food and Drug Administration recently made a decision ...
GSK and Vir Biotechnology struck up their influenza R&D collaboration three years ago, aiming to build on a respiratory drug relationship forged at the start of the Covid-19 pandemic. The British ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results